{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:49:04Z","timestamp":1793411344212,"version":"4.5.0"},"reference-count":11,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Reports of eosinophilic pneumonia (EP) as a side effect of dupilumab administration are limited in previous studies. Herein, we report two cases in which EP developed subsequent to the administration of dupilumab for eosinophilic chronic rhinosinusitis (ECRS). Case 1: A 55-year-old woman presented with ECRS, eosinophilic otitis media, and bronchial asthma, and was treated with dupilumab for ECRS. Five weeks later, fever and dyspnea developed, and infiltration shadows were observed in her lungs. The peripheral blood eosinophil count (PBEC) was 3848\/\u03bcL (26%), bronchoalveolar lavage fluid showed eosinophilic infiltration, and EP was subsequently diagnosed. Her condition improved following prednisolone treatment. Case 2: A 59-year-old man presented with fatigue and dyspnea after receiving dupilumab for ECRS. He had infiltrative shadows throughout his left lung field, and his PBEC was 4850\/\u03bcL (26.5%). Prednisolone was initiated, and his condition improved. EP developed in both patients during the period of elevated PBEC after dupilumab administration, and dupilumab was suspected to be the causative agent in their EP. Hence, EP should be considered as a differential diagnosis when fever and dyspnea appear following dupilumab administration.<\/jats:p>","DOI":"10.3390\/biom12121743","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T01:46:56Z","timestamp":1669254416000},"page":"1743","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["How Can Dupilumab Cause Eosinophilic Pneumonia?"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6164-0114","authenticated-orcid":false,"given":"Momoko","family":"Kurihara","sequence":"first","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, School of Medicine, Keio University, Tokyo 160-8582, Japan"},{"name":"Keio Allergy Center, Keio University Hospital, Tokyo 160-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0909-9409","authenticated-orcid":false,"given":"Katsunori","family":"Masaki","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, School of Medicine, Keio University, Tokyo 160-8582, Japan"},{"name":"Keio Allergy Center, Keio University Hospital, Tokyo 160-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiko","family":"Matsuyama","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, School of Medicine, Keio University, Tokyo 160-8582, Japan"},{"name":"Keio Allergy Center, Keio University Hospital, Tokyo 160-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5317-0885","authenticated-orcid":false,"given":"Masato","family":"Fujioka","sequence":"additional","affiliation":[{"name":"Keio Allergy Center, Keio University Hospital, Tokyo 160-8582, Japan"},{"name":"Department of Molecular Genetics, School of Medicine, Kitasato University, Kanagawa 252-0374, Japan"},{"name":"Clinical and Translational Research Center, Keio University Hospital, Tokyo 160-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reina","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, School of Medicine, Keio University, Tokyo 160-8582, Japan"},{"name":"Keio Allergy Center, Keio University Hospital, Tokyo 160-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saki","family":"Tomiyasu","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, School of Medicine, Keio University, Tokyo 160-8582, Japan"},{"name":"Keio Allergy Center, Keio University Hospital, Tokyo 160-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Sasahara","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, School of Medicine, Keio University, Tokyo 160-8582, Japan"},{"name":"Keio Allergy Center, Keio University Hospital, Tokyo 160-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keeya","family":"Sunata","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, School of Medicine, Keio University, Tokyo 160-8582, Japan"},{"name":"Keio Allergy Center, Keio University Hospital, Tokyo 160-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Asaoka","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, School of Medicine, Keio University, Tokyo 160-8582, Japan"},{"name":"Keio Allergy Center, Keio University Hospital, Tokyo 160-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuto","family":"Akiyama","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, School of Medicine, Keio University, Tokyo 160-8582, Japan"},{"name":"Keio Allergy Center, Keio University Hospital, Tokyo 160-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyuki","family":"Nishie","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, School of Medicine, Keio University, Tokyo 160-8582, Japan"},{"name":"Keio Allergy Center, Keio University Hospital, Tokyo 160-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misato","family":"Irie","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, School of Medicine, Keio University, Tokyo 160-8582, Japan"},{"name":"Keio Allergy Center, Keio University Hospital, Tokyo 160-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takae","family":"Tanosaki","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, School of Medicine, Keio University, Tokyo 160-8582, Japan"},{"name":"Keio Allergy Center, Keio University Hospital, Tokyo 160-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kabata","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, School of Medicine, Keio University, Tokyo 160-8582, Japan"},{"name":"Keio Allergy Center, Keio University Hospital, Tokyo 160-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Fukunaga","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, School of Medicine, Keio University, Tokyo 160-8582, Japan"},{"name":"Keio Allergy Center, Keio University Hospital, Tokyo 160-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation","volume":"75","author":"Allinne","year":"2020","journal-title":"Allergy"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cea.13491","article-title":"Mechanisms of dupilumab","volume":"50","author":"Harb","year":"2020","journal-title":"Clin. Exp. Allergy"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1136\/postgradmedj-2015-133443","article-title":"\u201cPhotographic negative of pulmonary oedema\u201d: A classical radiographic pattern of chronic eosinophilic pneumonia","volume":"91","author":"Cherian","year":"2015","journal-title":"Postgrad. Med. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2147\/JAA.S357548","article-title":"Real-world effectiveness of dupilumab for patients with severe asthma: A retrospective study","volume":"15","author":"Numata","year":"2022","journal-title":"J. Asthma Allergy"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/bjd.18434","article-title":"Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: Results from three phase III trials (Liberty AD SOLO 1, Liberty AD SOLO 2, Liberty AD Chronos)","volume":"182","author":"Wollenberg","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/ijd.15183","article-title":"Dupilumab treatment ameliorates clinical and hematological symptoms, including blood eosinophilia, in patients with atopic dermatitis","volume":"60","author":"Yamauchi","year":"2021","journal-title":"Int. J. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Katsuta, M., Ishiuji, Y., Matsuzaki, H., Yasuda, K.I., Kharma, B., Nobeyama, Y., Hayashi, T., Tokura, Y., and Asahina, A. (2021). Transient increase in circulating basophils and eosinophils in dupilumab-associated conjunctivitis in patients with atopic dermatitis. Acta Derm. Venereol., 101.","DOI":"10.2340\/00015555-3842"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.alit.2022.03.005","article-title":"Two cases of dupilumab-associated eosinophilic pneumonia in asthma with eosinophilic chronic rhinosinusitis: Il-5-driven pathology?","volume":"71","author":"Nishiyama","year":"2022","journal-title":"Allergol. Int."},{"key":"ref_11","first-page":"1455613221115043","article-title":"Co-Treatment with Steroid and Dupilumab for Eosinophilic Chronic Rhinosinusitis after Eosinophilic Pneumonitis Caused by Dupilumab","volume":"13","author":"Sudo","year":"2022","journal-title":"Ear Nose Throat J."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/12\/12\/1743\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:25:24Z","timestamp":1760145924000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/12\/12\/1743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,23]]},"references-count":11,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["biom12121743"],"URL":"https:\/\/doi.org\/10.3390\/biom12121743","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,23]]}}}